Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy Neal, J., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D. C., Bearz, A., Quantin, X., Palmero, R., Antic, V., Chun, E., Edubilli, T., Lin, Y., Huseni, M., Scheffold, C., Vervaet, P., Newsom-Davis, T. ELSEVIER SCIENCE INC. 2023: S39-S40View details for Web of Science ID 000995007600007